Get the Stockscreener App
4.98
1.19%
-0.06
After Hours:
5.00
0.02
+0.40%
Tscan Therapeutics Inc stock is traded at $4.98, with a volume of 630.77K.
It is down -1.19% in the last 24 hours and down -11.55% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$5.04
Open:
$5.05
24h Volume:
630.77K
Relative Volume:
1.86
Market Cap:
$265.93M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.7232
EPS:
-2.89
Net Cash Flow:
$-64.50M
1W Performance:
-4.23%
1M Performance:
-11.55%
6M Performance:
-37.28%
1Y Performance:
+94.53%
1-Day Range:
$4.93
$5.2666
1-Week Range:
$4.90
$5.43
52-Week Range:
$2.43
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
880 WINTER STREET, WALTHAM
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short Interest - MarketBeat
92,832 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by Troluce Capital Advisors LLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke Acquires 5,000 Shares - Defense World
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com South Africa
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com Canada
TScan therapeutics director buys $26,450 in company stock - Investing.com
TScan therapeutics director buys $26,450 in company stock - Investing.com India
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com UK
940,831 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Purchased by Great Point Partners LLC - Defense World
Great Point Partners LLC Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Bank of New York Mellon Corp Purchases New Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Sold by Marathon Trading Investment Management LLC - Defense World
When the Price of (TCRX) Talks, People Listen - Stock Traders Daily
TCRX Stock Sees Surge of Approximately 1.08% in Last Five Days - Knox Daily
Can Tscan Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Its Stock Has Paid Off Big Time For Tscan Therapeutics Inc - SETE News
TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
TScan Therapeutics Director Acquires 18% More Stock - Simply Wall St
How To Trade (TCRX) - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Zoran Zdraveski Sells 164,686 Shares of Stock - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Acquires $27,650.00 in Stock - MarketBeat
TScan Therapeutics director buys $56,100 in company shares - Investing.com India
TScan Therapeutics director buys $56,100 in company shares - Investing.com
TScan therapeutics executive sells over $950k in company stock By Investing.com - Investing.com Canada
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology (TCRX) - Seeking Alpha
TScan Therapeutics, Inc. (NASDAQ:TCRX) to Post FY2024 Earnings of ($1.07) Per Share, Lifesci Capital Forecasts - MarketBeat
FY2024 Earnings Estimate for TScan Therapeutics, Inc. Issued By Lifesci Capital (NASDAQ:TCRX) - Defense World
FY2024 EPS Estimates for TScan Therapeutics, Inc. Decreased by Analyst (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.31) Per Share (NASDAQ:TCRX) - Defense World
TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from HC Wainwright - Defense World
TScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by Needham & Company LLC - Defense World
TScan Therapeutics (NASDAQ:TCRX) Receives “Outperform” Rating from Wedbush - Defense World
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga
HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Vanguard Group Inc. - Defense World
TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024 - InvestorPlace
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates - MSN
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow
Sangamo Therapeutics (NASDAQ:SGMO) and TScan Therapeutics (NASDAQ:TCRX) Critical Survey - Defense World
(TCRX) On The My Stocks Page - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Up 67.7% in July - MarketBeat
Trading (TCRX) With Integrated Risk Controls - Stock Traders Daily
Tocqueville Asset Management L.P. Takes $1.69 Million Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Tocqueville Asset Management L.P. Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - American Banking and Market News
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):